3054643-04-5
3054643-04-5
Chemical Structure
PY-4Car2
- CAS No.: 3054643-04-5
- Formula:C29H30FN3O7
- Molecular Weight:551.56
InChIKey: OYMBRZPFKUVVIM-WRONEBCDSA-N
SMILES: OCCCCOC(N[C@@H]1C2=C3C(C(N4C3)=CC([C@](O)(C(OC5)=O)CC)=C5C4=O)=NC6=CC(F)=C(C)C(CC1)=C62)=O
Biological Activity: PY-4Car2 is a Camptothecin (HY-16560) derivative and a topoisomerase I inhibitor. PY-4Car2 functions as a warhead conjugated via a cleavable linker to the bispecific ADC TJ101. PY-4Car2 can be used as an ADC payload for the research of cancers[1][2].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PY-4Car2 | PY-4Car2 is a Camptothecin (HY-16560) derivative and a topoisomerase I inhibitor. PY-4Car2 functions as a warhead conjugated via a cleavable linker to the bispecific ADC TJ101. PY-4Car2 can be used as an ADC payload for the research of cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yangxin Zhang, et al. Abstract LB021: TJ102: A promising bispecific dual-payload ADC targeting CDH6 and folate receptor alpha (FRα) for the treatment of ovarian and kidney cancers. Cancer Res (2025) 85 (8_Supplement_2): LB021.
- [2]. Li Qi, et al. Abstract 2955: Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers. Cancer Res (2025) 85 (8_Supplement_1): 2955.
